Hydroxyzine,
does it really help with Improvement of anxiety, tension, and treatment response in adults with generalized anxiety disorder?
research showsHydroxyzine is rated C because placebo-controlled evidence signals short-term improvement in symptoms and treatment response in adults with generalized anxiety disorder. A Cochrane review of five trials and 884 participants found benefit over placebo, but the studies were few and at high risk of bias. A 12-week trial also improved response and remission, while long-term maintenance and modern first-line comparative evidence remain inadequate.
ads claimShort-term sedating symptom relief is sometimes expanded into treatment of the cause of chronic anxiety or equivalence to established first-line therapy.
Useful facts when choosing a product
- Hydroxyzine is a prescription first-generation H1 antihistamine with central sedation and anticholinergic activity and may be used for short-term anxiety symptoms.
- Drowsiness and slower reactions can impair driving or machinery use, and alcohol or other sedatives should be avoided.
- Dry mouth, constipation, and urinary retention can occur, while QT prolongation requires review in people with cardiac disease, electrolyte abnormalities, or other QT-prolonging drugs.
What the research actually shows
Cochrane reviewed five randomized trials with 884 participants and found a signal of benefit over placebo, but concluded that high risk of bias and few studies prevented recommending hydroxyzine as a reliable first-line treatment. The 12-week multicenter double-blind Llorca 2002 trial reported that hydroxyzine 50 mg daily improved HAM-A scores, response, and remission versus placebo.
Why this is classified as C (50)
Placebo-controlled benefit and improved response and remission at 12 weeks are positive, but five trials, 884 participants, high risk of bias, and no long-term evidence support C with 50 points.
Counterpoint. It can be a prescription option for rapid short-term relief in some adults, but long-term GAD management requires a separate plan.
Rejudgment record. Cross-check applied — Accepted the positive placebo-controlled signal but applied C for limited positive evidence because trials were few and short, risk of bias was high, outcomes were subjective, and long-term maintenance evidence was absent
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Relief of anxiety and tension in adult generalized anxiety disorder | C | A positive placebo-controlled signal exists, but trials are few, short, and at risk of bias. |
| Improved treatment response in adult generalized anxiety disorder | C | Response and remission improved at 12 weeks, but independent replication and long-term data are limited. |
| Long-term sustained benefit | C | Evidence is inadequate to extend short-term positive findings to sustained long-term benefit. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Guaiana G et al. 2022 | Cochrane systematic review of randomized trials | 884 | Cochrane academic review | Anxiety symptoms, response, dropout, and adverse events | Hydroxyzine was more effective than placebo, but trials were few and at high risk of bias. | Key synthesis |
| Llorca PM et al. 2002 | Twelve-week multicenter randomized double-blind placebo- and active-controlled trial | 334 | Possible commercial context as reported; consult the article | HAM-A, response, remission, and clinical global impression | Hydroxyzine 50 mg daily improved anxiety scores, response, and remission versus placebo. | Direct short-term efficacy evidence |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-23).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none
Cite this verdict
[Chamgap] Hydroxyzine x improvement of anxiety, tension, and treatment response in adult generalized anxiety disorder — Evidence Grade C·50. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/mood/hydroxyzine-generalized-anxiety-disorder-symptom-response/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.